Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.

Deng, Mi; Gui, Xun; Kim, Jaehyup; Xie, Li; Chen, Weina; Li, Zunling; He, Licai; Chen, Yuanzhi; Chen, Heyu; Luo, Weiguang; Lu, Zhigang; Xie, Jingjing; Churchill, Hywyn; Xu, Yixiang; Zhou, Zhan; Wu, Guojin; Yu, Chenyi; John, Samuel; Hirayasu, Kouyuki; Nguyen, Nam; Liu, Xiaoye; Huang, Fangfang; Li, Leike; Deng, Hui; Tang, Haidong; Sadek, Ali H; Zhang, Lingbo; Huang, Tao; Zou, Yizhou; Chen, Benjamin; Zhu, Hong; Arase, Hisashi; Xia, Ningshao; Jiang, Youxing; Collins, Robert; You, M James; Homsi, Jade; Unni, Nisha; Lewis, Cheryl; Chen, Guo-Qiang; Fu, Yang-Xin; Liao, X Charlene; An, Zhiqiang; Zheng, Junke; Zhang, Ningyan; Zhang, Cheng Cheng.
Nature; 562(7728): 605-609, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30333625
Immune checkpoint blockade therapy has been successful in treating some types of cancer but has not shown clinical benefits for treating leukaemia1. This result suggests that leukaemia uses unique mechanisms to evade this therapy. Certain immune inhibitory receptors that are expressed by normal immune cells are also present on leukaemia cells. Whether these receptors can initiate immune-related primary signalling in tumour cells remains unknown. Here we use mouse models and human cells to show that LILRB4, an immunoreceptor tyrosine-based inhibition motif-containing receptor and a marker of monocytic leukaemia, supports tumour cell infiltration into tissues and suppresses T cell activity via a signalling pathway that involves APOE, LILRB4, SHP-2, uPAR and ARG1 in acute myeloid leukaemia (AML) cells. Deletion of LILRB4 or the use of antibodies to block LILRB4 signalling impeded AML development. Thus, LILRB4 orchestrates tumour invasion pathways in monocytic leukaemia cells by creating an immunosuppressive microenvironment. LILRB4 represents a compelling target for the treatment of monocytic AML.
Selo DaSilva